ARCH Venture Partners
Venture capitalChicago · Seed–Growth · 54 people tracked
Also known as Arch Asset Management Inc · ARCH Venture · ARCH VENTURE CORP · ARCH VENTURE MANAGEMENT LLC
Investment thesis
ARCH Venture Partners takes a contrarian, bold approach to venture investing, founding and building companies around revolutionary science and technologies intended to improve people's lives. The firm follows the science to identify opportunities and adopts a long-term view when building companies, remaining flexible in its approach and sizing investments in each portfolio company as needed. It leverages an extended network of partners to help companies through their formation stages and support their growth to full potential.
Source: firm website, verified Aug 27, 2026.
Team · 54 people
from the firm's website & curated & public directories
Founder mafia
The ARCH Venture Partners mafia →14 people who came through ARCH Venture Partners went on to found or lead other companies.
+ 2 more
What they invest in
from 156 of 196 portfolio companiesBiotech ×130Medical Devices ×71Healthtech ×55Deep Tech ×52AI & Machine Learning ×36Digital Health ×21Advanced Manufacturing ×8Enterprise Software ×7
HQs:United States×119United Kingdom×2Switzerland×1China×1Germany×1India×1
Who they back
founder profiles across 75 portfolio companiesFounding team size:solo founder×292 founders×153 founders×194+ founders×12
Where their founders studiedfrom 37 founders with education data
University of California, Berkeley ×4Harvard University ×3Princeton University ×3Columbia University Vagelos College of Physicians and Surgeons ×2Harvard Business School ×2Northwestern University ×2The Johns Hopkins University School of Medicine ×2The Wharton School ×2
Where their founders worked beforefrom 42 founders with career history
Biotechnology Innovation Organization ×5Stanford University ×5Brigham and Women's Hospital ×4Harvard University ×3University of California, San Francisco ×3Aisling Capital ×2Amgen ×2Farcast Biosciences ×2
21 founders hold a PhD · 4 hold an MBA (of 34 with degree data) · backed the same founder in 2+ companies: 2 founders
Investments · 196 tracked
founders shown can be your intro pathBy year:2026 · 92025 · 112024 · 192023 · 72022 · 82021 · 112020 · 22019 · 22018 · 72017 · 62016 · 42015 · 13104 dated
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)David Liu(Co-founder)Allan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)Svetlana Makhni(Chief Financial Officer)
Co-investorsGV (Google Ventures)Newpath PartnersF-Prime CapitalOUP (Osage University Partners)Samsara BioCapital
908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications.
Deep TechDefense TechHardwareMedical DevicesBoston, US
Kevin J. Knopp, PhD(CEO & Co-founder)Christopher Brown(Executive Officer)inKevin Knopp(Executive Officer, Director)inJoseph Griffith IV(Executive Officer)
BoardCorey Steffek(Director)
Board seatKeith CrandellKevin Hrusovsky· per SEC Form D
Co-investorsRazor's Edge VenturesUTECAramco VenturesNorthpond Ventures
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder and Inventor)inJ. Keith Joung(Founder and Inventor)inFeng Zhang(Founder and Inventor)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)
Board seatRobert NelsenKristina Burow· per SEC Form D
Co-investorsDreamers VCEight Roads VenturesF-Prime CapitalForesite CapitalGV (Google Ventures)HongShan Capital Group+1 more
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)in
BoardBenjamin Cravatt, Ph.D.(Director)Carolyn Ng, Ph.D.(Director)Jakob Loven, Ph.D.(Director)Ho Sung Cho, Ph.D.(Director)
Board seatKristina Burow· per SEC Form D
Co-investorsNextech InvestRA Capital
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)Joe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)Helen Collins(Chief Medical Officer)Ben Hohl(Chief Financial Officer and Head of Corporate Development)
Board seatRichard Heyman· per SEC Form D · $90M raise · filed Apr 2024
Co-investors5AM VenturesOrbiMedPfizer Venture InvestmentsRoche Venture Fund
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Joshua Bilenker, M.D.(Director)
Board seatKristina BurowRobert Nelsen· per SEC Form D
Co-investorsBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Samsara BioCapital
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inJosh Ofman(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)in
Board seatRobert Nelsen· per SEC Form D
Co-investorsAmino CapitalBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu VenturesFelicis Ventures+8 more
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
Board seatRobert NelsenKristina Burow· per SEC Form D
Co-investorsCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier PartnersSoftBank Vision Fund+2 more
Quanterix develops technology for highly sensitive detection of protein biomarkers using non-invasive sample types, aimed at early disease detection and prevention.
BiotechDigital HealthHealthtechMedical DevicesLexington, US
David Walt(Director)inErnest Orticerio(Executive Officer)Ernest Oriticerio(Executive Officer)
BoardJohn Connolly(Director)Paul Meister(Director)
Board seatKeith Crandell· per SEC Form D
Co-investorsFoothill VenturesKhosla VenturesNovalis LifeSciences
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)inTimothy Springer(Director)
BoardAmir Nashat(Director)inKatrine Bosley(Director)Michael Gilman(Director)
Board seatKristina Burow· per SEC Form D
Co-investorsAisling CapitalEcoR1 CapitalPolaris Partners
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Alan Buckler(Executive Officer)
BoardAmir Nashat(Director)in
Board seatKristina Burow· per SEC Form D · $47M raise · filed Jan 2018
Co-investorsSamsara BioCapitalPolaris Partners
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO and Board Member)inMichael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)inEric Green(Executive Officer)in
BoardJames I. Healy(Director)
Board seatRobert Nelsen· per SEC Form D
Co-investorsForesite CapitalHAWKTAILPureTech HealthSofinnova Ventures
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)in
BoardPaul Conley(Director)inFred Craves(Director)in
Board seatKeith Crandell· per SEC Form D
Co-investors+ND Capital3E Bioventures CapitalAsset Management CompanyBay City CapitalBlack Opal VenturesDentsu Ventures+7 more
Nasdaq-listed clinical-stage immunology company in San Francisco developing hepatitis B/D antivirals and licensed T-cell engagers.
BiotechSan Francisco, US
Herbert Virgin(Executive Officer)Howard Horn(Executive Officer)Alex Bangs(Executive Officer)
BoardGeorge Scangos(Executive Officer, Director)Robert More(Director)
Board seatRobert NelsenKristina BurowVicki Sato· per SEC Form D
Co-investorsAlta PartnersSoftBank Group
NASDAQ-listed (VYGR) biotech in Lexington, MA developing AAV gene therapies and antibodies for neurological diseases.
BiotechLexington, US
Robin Swartz(Executive Officer)Alfred Sandrock(Executive Officer, Director)Peter Pfreundschuh(Executive Officer)Steven Hyman(Director)James A. Geraghty(Director)Grace Colon(Director)
Board seatGeorge Scangos· per SEC Form D · $20M raise · filed Jan 2024
Co-investorsThird Rock Ventures
Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
BiotechHealthtechMedical Devices
Brian Goff(Chief Executive Officer)inLewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)Shin-San Michael Su, Ph.D.(Founding scientist and first employee)Craig B. Thompson, M.D.(Founder)
Co-investorsThird Rock VenturesFlagship VenturesSamsara BioCapital
Denali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Marc Tessier-Lavigne(Director)Ryan Watts(Executive Officer, Director)inAlexander O. Schuth(Executive Officer)inCarole Ho(Executive Officer)Steve E. Krognes(Director)
BoardDavid P. Schenkein(Director)in
Co-investorsEcoR1 CapitalF-Prime CapitalForesite CapitalGV (Google Ventures)
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)Gary Yeung, CFA(Chief Business Officer)in
BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)
PartnerKristina Burow· quoted
Co-investorsAndreessen HorowitzEvolution VC PartnersFrazier Life SciencesCity Hill VenturesColt VenturesLifeSci Venture Partners
Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering.
AI & Machine LearningBiotechDeep TechSomerville, US
Gevorg Grigoryan(Co-Founder & Chief Technology Officer)in
Co-investorsFlagship PioneeringMarch Capital PartnersNVentures
Kardigan develops targeted cardiovascular treatments through a discovery and translational research platform, with a pipeline of late-stage drug candidates aimed at functional cures for cardiovascular disease.
AI & Machine LearningBiotechHealthtechMedical Devices
Co-investorsCatalio Capital Management, LPT. Rowe Price
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
TROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inHEIDI HENSON(Executive Officer)inANNETTE NORTH(Executive Officer)
Co-investorsAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalNextech InvestOUP (Osage University Partners)
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzForesite CapitalFrazier Life SciencesGV (Google Ventures)Janus Henderson InvestorsVenrock Healthcare Capital Partners
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech InvestRA Capital+5 more
PerkinElmer is a scientific instrument and technology company that provides analytical tools and services for research, diagnostics, and life sciences applications.
BiotechDeep TechEnterprise SoftwareHealthtechMedical DevicesWaltham, US
James M. Mock(Executive Officer)Andrew Okun(Executive Officer)inJoel S. Goldberg(Executive Officer)Prahlad Singh(Executive Officer, Director)inTajinder Vohra(Executive Officer)in
BoardSylvie Gregoire(Director)
Co-investorsAmpersandPartners for GrowthPartners for Growth (PFG)
Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.
BiotechDeep TechHealthtechMedical DevicesFramingham, US
Anand Varadan(Director)Richard Batycky(Director)Peter Ludlum(Interim CEO; Interim CFO)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)
BoardRichard Conley(Director)
Co-investors5AM VenturesPolaris Partners
Rapport is a biopharmaceutical company developing novel therapeutics.
BiotechHealthtechMedical Devices
Abe Ceesay(President)Cheryl GaultDr. Sevigny
Co-investorsSofinnova Ventures
Basking Biosciences develops therapeutics for thrombosis, vascular biology, and ischemic disease.
BiotechDigital HealthHealthtechMedical DevicesCary, US
Shahid Nimjee(Co-founder, Chief Scientific Officer and Stroke Clinical Lead)inBruce Sullenger(Co-founder)Julia Owens(Executive Officer, Director, Promoter)inRichard Shea(Executive Officer, Director, Promoter)in
BoardHannah Chang(Director)Aiden Aceves(Director)in
Board seatSteve Gillis· per SEC Form D
Co-investorsInsight PartnersBroadview VenturesSolas BioVenturesRev1 VenturesRTW Investments L.P.
Cytrellis develops medical device technologies focused on aesthetic and reconstructive treatments, with expertise spanning dermatology, plastic surgery, and wound healing applications.
BiotechHealthtechMedical DevicesWoburn, US
Rox Anderson, MD(Founder, Medical / Technology Advisor)William G. Austen, Jr. MD(Founder, Medical / Technology Advisor)Doug Levinson, PhD(Founder)Denise Dajles, PhD(President & CEO)John McDonough(Executive Officer, Director)inDavid Stone(Executive Officer)in
Board seatKeith Crandell· per SEC Form D
IngredientWerks is a molecular farming company that engineers plants to produce plant-based proteins and ingredients for the alternative protein market.
AgTechBiotechFoodTechWoburn, US
Matt Plavan(Chief Executive Officer)inMichael Raab(R&D Lead)Jeremy Schley-Johnson(Vice President)Steve Snyder(Director)James Schultz(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsOpen PrairieCultivian Sandbox VenturesSandbox Industries
Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)Rob Carson(Chief Executive Officer)inSimona Levi(Chief Legal Officer)in
Board seatKeith Crandell· per SEC Form D
Co-investorsNorthpond Ventures6 Dimensions CapitalApplied VenturesKilonova CapitalPura Vida InvestmentsRazor's Edge Ventures+2 more
Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inRobert Carson(Executive Officer, Director)Terry Lo(Director)inSeth Benson(Executive Officer)inSimona Levi(Executive Officer)in
Board seatKeith Crandell· per SEC Form D
Co-investorsM VenturesNorthpond VenturesNovalis LifeSciences
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
Feng Zhang, Ph.D.(Scientific Founder & Board Observer)Akin Akinc, Ph.D.(Chief Executive Officer & Board Director)
Co-investorsLux CapitalF-Prime CapitalGV (Google Ventures)JDRF T1D FundNewpath Partners
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inDamien McDevitt(President and Chief Executive Officer)in
Co-investorsLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32Frazier Life Sciences+3 more
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)Anthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inAmeet Nathwani, M.D.(Executive Officer, Director)in
Co-investorsEcoR1 CapitalSamsara BioCapital6 Dimensions CapitalGeneral CatalystInnovation EndeavorsLeaps by Bayer+5 more
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtech
Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)
Co-investorsAtlas VentureSanofi Ventures5AM Ventures
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical Devices
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)
Co-investorsNewpath PartnersTaiho Ventures, LLC
Moleculent develops biological discovery and disease understanding tools for scientists.
AI & Machine LearningBiotechDeep Tech
Fredrik Roos(CTO & Co-founder)in
Co-investorsEIR Ventures
Paradigm Health operates a platform that increases patient access to clinical trials through a provider-facing infrastructure combined with AI-powered research technology.
AI & Machine LearningHealthtechMedical DevicesSaaSColumbus, US
Kent Thoelke(Founder and Chief Executive Officer)inJonathan Hirsch(Chief Strategy and Growth Officer)
Co-investorsGeneral CatalystLux CapitalGV (Google Ventures)Magnetic VenturesMubadala Capital
Paradigm Health provides technology and services that integrate with healthcare provider organizations to improve the clinical trial process.
BiotechDigital HealthHealthtech
Kent Thoelke(Founder & CEO)Jonathan Hirsch(Chief Strategy and Growth Officer)Jay Trepanier(Chief Financial Officer)Elijah Meerson(Chief Technology Officer)Michelle Lee(Chief Operating Officer)
Co-investorsGeneral CatalystGV (Google Ventures)Lux CapitalJobsOhio Ventures
Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.
BiotechHealthtechLongevity
William Lowry(PhD)Christina Weng(Chief Medical Officer)Nathan Wheeler(Chief Operating Officer)
BoardDaniel Gil(PhD)
Co-investorsGV (Google Ventures)HAWKTAILVisionary VenturesYK Bioventures
Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.
BiotechDeep TechHealthtechMedical Devices
Michal Minczuk(Co-Founder)Gabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Jay Parrish(Chief Executive Officer & Chairman of the Board)in
Co-investorsCambridge Innovation CapitalEIR VenturesGV (Google Ventures)HealthCap
RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.
BiotechDigital HealthMedical DevicesBasel, CH
Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)Katherine High(CEO)
Co-investorsNovartis Venture FundBioGeneration VenturesF-Prime CapitalGV (Google Ventures)
Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.
BiotechMedical Devices
Tony Estrada(President & Chief Executive Officer)in
Co-investorsF-Prime Capital
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtech
Kris ElveruminTodd Bazemore(Chief Executive Officer)
BoardRodger Novak(Chair)
Co-investors+ND CapitalForbionVenrockFast Track InitiativeNextech InvestNovalis LifeSciences+2 more
Fabless US semiconductor company making ultralow-power non-volatile memory, ASICs and IoT embedded systems; acquired by Dialog in 2020.
Sunnyvale, US
Narbeh Derhacobian(Executive Officer, Director)inRon Shelton(Executive Officer)in
BoardMatt Boyle(Director)Alexei Andreev(Director)Barry Cox(Director)
Board seatKeith Crandell· per SEC Form D · $12.5M raise · filed Sep 2015
US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.
AgTechResearch Triangle Park, US
Scott Uknes(Manager)inEric Ward(Manager)Paul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)
BoardThomas Dietz(Manager)
Board seatKristina Burow· per SEC Form D · $34.5M raise · filed Aug 2015
Co-investorsAliment CapitalBlue Horizon CorporationPontifax AgTechNovalis LifeSciencesPolaris Partners
Agrivida develops enzyme technology for animal feed and nutrition, improving efficiency in poultry, swine, and other livestock production.
AgTechBiotechFoodTechMassachusetts, US
R. Michael Raab(Executive Officer)Daniel Meagher(Executive Officer, Director)Jeremy Schley Johnson(Executive Officer)
BoardRob Johnson(Director)Mark Austin(Director)Robert Bucklin(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsMiddleland CapitalPresidio VenturesCultivian Sandbox Ventures
Alzheon is a clinical-stage biopharmaceutical company developing oral small-molecule drugs for Alzheimer's disease and other neurodegenerative disorders, with a Phase 3 program for its lead compound valiltramiprosate (ALZ-801).
BiotechDeep TechHealthtechFramingham, US
Martin Tolar, M.D., Ph.D.(President and Chief Executive Officer)Martin Tolar(Executive Officer, Director)inMartin Tolar, MD, PhD(Founder)inGlenn E. Pauly(Chief Commercial Officer)inSusan Abushakra, M.D.(Chief Medical Officer)inJohn Hey, Ph.D.(Chief Scientific Officer)
Board seatScott Minick· per SEC Form D · filed Feb 2015
Apex Neuro Holdings is a Brooklyn-based company founded in 2017; no usable public sources were found about it.
Brooklyn, US
Lis Rhodes(Executive Officer)Francois Kress(Executive Officer, Director)
BoardZen Chu(Director)Adam D'Augelli(Director)in
Board seatRobert Nelsen· per SEC Form D · $10M raise · filed Mar 2022
Co-investorsM13True Ventures
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)WINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)ANNIE HAZLEHURST(Director)
BoardDAVID R. WALT(Director)in
Board seatKeith Crandell· per SEC Form D
Co-investorsIllumina VenturesOno Venture Investment, Inc.TCG CrossoverThird Rock Ventures
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
BiotechChapel Hill, US
Robin Walker(Executive Officer)Christopher Courts(Executive Officer)Jorge Bartolome(Executive Officer, Director)
BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)
Board seatPaul Berns· per SEC Form D
Co-investorsBain Capital Life SciencesGV (Google Ventures)Access BiotechnologyMaverick CapitalSaturn PartnersViking Global Investors
Seattle 'scientific wellness' startup that paired genetic, blood and microbiome testing with health coaching; closed in 2019.
HealthtechSeattle, US
Nathan Price(Director)Clayton Lewis(Executive Officer, Director)
BoardTim Kilgallon(Director)
Board seatRobert Nelsen· per SEC Form D · $30M raise · filed Jun 2017
Co-investorsCorewell Health Ventures
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Board seatKristina Burow· per SEC Form D
Co-investorsCanaan PartnersMonograph Capital PartnersPfizer Venture InvestmentsSamsara BioCapitalNewpath Partners
Agricultural biotechnology company using boron-based synthetic chemistry to develop next-generation fungicides.
Research Triangle Park, US
Tracy Jackson(Executive Officer)John Dombrosky(Executive Officer)
BoardJoel Marcus(Director)Stephen Benkovic(Director)Paul Schimmel(Director)
Board seatKristina Burow· per SEC Form D · $10.5M raise · filed Mar 2017
Cooledge builds large-scale luminous ceilings and acoustic luminaires that emulate natural light and absorb sound.
Advanced ManufacturingConstruction TechHardwareRichmond
William Sims(Director)Kirk A. Washington(Director)Geoff Catherwood(Director)Thomas Bilbrough(Director)Calvin Wade Sheen(Executive Officer, Director)Jim Miller(Director)
Board seatClinton Bybee· per SEC Form D · $9.1M raise · filed Jan 2016
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Board seatSteven Gillis· per SEC Form D
Co-investorsAlta PartnersCatalio Capital Management, LPKhosla VenturesOUP (Osage University Partners)b2ventureKendall Capital Partners
Elephas develops elive, a live-tissue platform technology that predicts immunotherapy response in cancer patients by measuring real-time immune activity in intact tumor tissue.
BiotechDigital HealthHealthtechMedical DevicesMadison, US
Jonathan Oliner(Executive Officer)inManeesh Arora(Founder)inMichelle B. Arora(Director)Terrence P. Brady(Executive Officer)
Board seatPaul Berns· per SEC Form D
Co-investorsNorthpond VenturesSands Capital Ventures
San Francisco biotechnology company that filed a $400,000 Regulation D equity offering in April 2023.
BiotechSan Francisco, US
Sung Lee(Executive Officer, Director)Natascha Schill(Executive Officer, Director)Vanina de Verneuil(Executive Officer)
BoardThomas Hecht(Director)Johanna Friedl-Naderer(Director)
Board seatGeorge Scangos· per SEC Form D · $400K raise · filed Apr 2023
Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.
BiotechSeattle, US
Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)
BoardPaulina Hill(Director)
Board seatSteven Gillis· per SEC Form D
Co-investorsOUP (Osage University Partners)Polaris Partners
South Dakota holding entity that owns a majority stake in the High Plains Processing oilseed crush plant near Mitchell, SD.
AgTechVolga, US
Mark Hyde(Executive Officer)Gary Goplen(Director)Spencer Enninga(Director)Lewis Bainbridge(Director)Thomas J Kersting(Executive Officer)Mark Mickelson(Director)
Board seatRobert Nelsen· per SEC Form D · $230M raise · filed Oct 2022
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(CEO & Founder)inDuane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in
BoardVijay Pande(Director)in
Board seatRobert Nelsen· per SEC Form D
Co-investorsAndreessen HorowitzForesite CapitalGV (Google Ventures)HOF CapitalSoftBank Vision FundBezos Expeditions+5 more
Seattle CAR-T and TCR cancer immunotherapy company founded in 2013 and acquired by Celgene for $9 billion in 2018.
BiotechSeattle, US
Hans Bishop(Executive Officer, Director, Promoter)Richard Klausner(Director, Promoter)Bernard J. Cassidy(Executive Officer)Robert Azelby(Executive Officer)Sunil Agarwal(Executive Officer)Rupert Vessey(Director)
Board seatRobert Nelsen· per SEC Form D
Co-investorsAlaska Permanent Fund Corporation
Ann Arbor-founded biopharmaceutical company developing small molecule immunomodulators for autoimmune diseases and cancer.
BiotechAnn Arbor, US
Gary Glick(Executive Officer, Director)Paul Sekhri(Executive Officer)Kathleen M. Metters(Executive Officer, Director)
BoardRobert Kamen(Director)inMichael Hayden(Director)Michael Steinmetz(Director)
Board seatKristina BurowSteven Gillis· per SEC Form D · filed Jun 2015
Co-investorsCanaan PartnersThird Rock Ventures
Xtremity makes the XtremityTT, a thermoformable definitive prosthetic socket system built from an injection-molded, carbon-reinforced polymer preform that clinicians can heat, form, and assemble in about an hour and re-adjust via spot-heating.
HardwareHealthtechMedical DevicesNew MaterialsAspen, US
Mark Joseph(Founder / Inventor & Product Designer)Miguelangel Sosa(Executive Officer, Director)Amy Hill(Executive Officer)Scott Ward(Executive Officer)
Board seatRobert Nelsen· per SEC Form D · $15M raise · filed Jun 2021
Co-investorsDecheng CapitalRsquared
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardAmir Nashat(Director)in
Board seatKristina BurowRichard Heyman· per SEC Form D · $37.8M raise · filed Nov 2016
Co-investorsage1EcoR1 CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+2 more
Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.
BiotechHealthtechMedical DevicesNew York, US
Clive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)Brian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)
Board seatKristina BurowPaul Berns· per SEC Form D
Co-investorsAlpha Wave GlobalF-Prime CapitalGV (Google Ventures)RA CapitalSoftBank Vision FundNewpath Partners
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.
AI & Machine LearningHealthtechMedical DevicesSan Diego, US
Mark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)
Board seatKristina BurowPaul Berns· per SEC Form D
Co-investorsOrbiMedSanofi Ventures
Nanosys develops Quantum Dot technology and materials, providing samples, R&D collaboration, and scaled production for partners building display and other advanced-material products.
Advanced ManufacturingDeep TechHardwareNew MaterialsSemiconductorsMilpitas, US
Jason Hartlove(Executive Officer, Director)inJian Chen(Executive Officer)inRussell Kempt(Executive Officer)inNoland Granberry(Executive Officer)in
BoardSteven Goldby(Director)
Board seatKeith Crandell· per SEC Form D · $10M raise · filed Mar 2015
Co-investorsProspect Venture PartnersStructural CapitalTEL Venture Capital, Inc.Venrock
Technology-focused biomanufacturing CDMO producing biologics, vaccines, nucleic acids and cell and gene therapies.
La Jolla, US
Board seatRobert Nelsen· per SEC Form D · $755M raise · filed Jan 2021
Co-investors8VC
RNA therapeutics company with a chip-based mRNA manufacturing platform; acquired by Medici Therapeutics in November 2025.
BiotechEmeryville, US
Igor Khandros(Executive Officer, Director)
Board seatRobert Nelsen· per SEC Form D
Co-investors+ND CapitalBluebird Ventures
Menlo Park biotech applying a data and analytics platform plus diagnostic testing to multiple sclerosis and neurodegenerative care.
HealthtechMenlo Park, US
William Hagstrom(Executive Officer, Director)Melinda Thomas(Executive Officer)Mark Weeks(Executive Officer)
BoardBrook Byers(Director)inThomas Hawes(Director)A. Grant Heidrich III(Director)
Board seatGeorge Scangos· per SEC Form D · $53.7M raise · filed Mar 2025
Co-investorsKleiner Perkins
A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.
BiotechAustin, US
Jason Ehrlich(Executive Officer, Director)
BoardTravis Murdoch(Director)Fred Cohen(Director)Alaa Halawa(Director)Cariad Chester(Director)
Board seatPaul Berns· per SEC Form D
Co-investorsMonograph Capital PartnersMC Healthcare VenturesTCG Crossover
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)Clifford J. Stocks(Director, Executive Officer)Kamal D. Puri(Executive Officer)Chris Russell(Executive Officer)Russ Hawkinson(Executive Officer)
Board seatSteven Gillis· per SEC Form D
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersBering CapitalIntervest+3 more
Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.
BiotechHealthtechMedical DevicesRedwood City, US
Irv Weissman(Cofounder, Scientific Advisor, Board Director)Ravi Majeti(Cofounder, Scientific Advisor, Board Observer)Amira Barkal(Principal Founder, Scientific Advisor, Board Director)inRoy Maute(Cofounder & Chief Executive Officer)in
BoardJacob Vogelstein(Director)
Board seatSteven Gillis· per SEC Form D
Co-investorsCatalio Capital Management, LP
Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.
BiotechHealthtechSeattle, US
CHRISTOPHER TOOMBS(Executive Officer)LINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)
BoardThong Le(Executive Officer, Director, Promoter)
Board seatSteven Gillis· per SEC Form D
Co-investorsACCELERATOR LIFE SCIENCE PARTNERSWRF Capital
Durham, NC company building multi-camera array microscope (MCAM) systems for high-throughput live imaging in life-science labs.
BiotechDurham, US
Roarke Horstmeyer(Director)inMark Harfouche(Executive Officer, Director)inRobert Horstmeyer(Director)Margaret Aery(Executive Officer)inGregor Horstmeyer(Executive Officer, Director)
Board seatSean KendallPatrick Weiss· per SEC Form D · $31M raise · filed Mar 2026
Co-investorsThe E14 Fund
Rezo maps disease networks to find insights into disease biology for drug discovery.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Nevan Krogan(Co-Founder)Sourav Bandyopadhyay(Co-Founder)Norbert Bischofberger(Co-Founder)Natalia Jura(Co-Founder)George Scangos(Co-Founder)Kevan Shokat(Co-Founder)
Board seatGeorge Scangos· per SEC Form D · $80.1M raise · filed Aug 2025
Co-investorsAndreessen HorowitzNorwest Venture PartnersHAWKTAILSR One Capital ManagementValkyrie Ventures Management, Llc
Rippl delivers evidence-based dementia care through a combination of technology and human support for people living with dementia and their families.
Digital HealthHealthtechSeattle, US
Kris Engskov(Co-founder & CEO)inRobert Nelsen(Co-Founder & Board Chair)Paul Engskov(Executive Officer, Director)
BoardHolly Maloney(Director)inIyah Romm(Director)Ryan Watts(Director)
Board seatRobert Nelsen· per SEC Form D
Co-investors1843 CapitalCity LightEquitage Ventures, L.L.C.GV (Google Ventures)General Catalyst
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Steve Harr(President and Chief Executive Officer)
Board seatRobert Nelsen· per SEC Form D
Co-investorsAmerican Family VenturesF-Prime CapitalFlagship PioneeringInnovating CapitalJDRF T1D FundManta Ray Ventures+1 more
EnergySan Diego, US
James E. Levine(Chief Executive Officer and President)James Astwood(Senior Vice President of Product Management)James Butler(Vice President of Legal Affairs and Intellectual Property)Thomas Willardson(Chief Financial Officer)
BoardSteven Goldby(Director)Eric Luo(Director)
Board seatRobert Nelsen· per SEC Form D · $92M raise · filed Dec 2015
Co-investorsVenrock
Semprius was a Durham, NC developer of micro-transfer-printed high-concentration photovoltaic solar modules, spun out of the University of Illinois.
Durham, US
JOHN ROGERS(Executive Officer, Director)JOSEPH CARR(Executive Officer, Director)HELENA YEE(Executive Officer)JACK BARRY(Executive Officer)
BoardGREG WOLF(Director)
Board seatClinton Bybee· per SEC Form D · $1.7M raise · filed Jan 2015
BiotechNew Haven, US
Aaron Ring(Manager)inBeatrice McQueen(Executive Officer)
BoardJim Tananbaum(Manager)
Board seatSabah Oney· per SEC Form D · $10M raise · filed Feb 2024
Co-investorsAxial VC
Westlake Village dermatology company developing late-stage topical and photoparticle skin treatments; assets sold to Sebacia in 2020.
BiotechWeslake Village, US
Frederick C. Beddingfield III(Executive Officer, Director)Todd Harris(Director, Executive Officer)inDiane Stroehmann(Executive Officer)inPaul F. Lizzul(Executive Officer)inRic Peterson(Executive Officer)inTimothy K. Andrews(Executive Officer)
Board seatRobert NelsenKristina Burow· per SEC Form D · $40.5M raise · filed May 2017
San Francisco catalyst company that converted natural gas to ethylene and fuels; acquired by McDermott in 2019.
San Francisco, US
Edward J Dineen(Executive Officer, Director)Jeffrey P. Wood(Executive Officer)
BoardMichel Maloof(Director)Leighton Read(Director)Paula Reynolds(Director)
Board seatClinton Bybee· per SEC Form D · $25.7M raise · filed Jan 2016
Co-investorsLux Capital
Boston-area biotech developing gene therapies for genetic causes of pediatric hearing loss.
BiotechCambridge, US
Giampiero De Luca(Director)Jodi A. Cook(Executive Officer, Director)Will McLean(Executive Officer)
Board seatSteve Gillis· per SEC Form D
Slingshot Biosciences makes synthetic cell mimics used as standardized reference controls for flow cytometry and cell-based assays.
Emeryville, US
Jeff Kim(Founder)inAdam Wieschhaus(Director)Ronald J. Silberman(Director)
Board seatCorey RitterPatrick Weiss· per SEC Form D
Co-investorsAnterra CapitalNorthpond Ventures
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Board seatSteven Gillis· per SEC Form D · $125.5M raise · filed Jun 2026
Co-investorsVida VenturesLeaps by BayerFoothill VenturesIllumina VenturesMedical Excellence CapitalVivo Capital+1 more
Cambridge, MA gene-control biopharma that developed tamibarotene for RARA-overexpressing blood cancers; now in wind-down.
Cambridge, US
Board seatRobert NelsenVicki Sato· per SEC Form D · $11.4M raise · filed Feb 2018
Co-investorsPolaris PartnersSamsara BioCapital
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in
BoardAli Satvat(Director)David Schenkein(Director)in
Board seatKristina Burow· per SEC Form D
Co-investorsAisling CapitalOrbiMedCasdin CapitalFidelity InvestmentsGV (Google Ventures)Rock Springs Capital+1 more
Trelys, Inc. is a small California commercial biotechnical research company led by CEO Jay Kouba.
BiotechHayward, US
Jay Kouba(Executive Officer, Director)Thomas Erickson(Director)Doug Cameron(Director)
Board seatKristina Burow· per SEC Form D · $80K raise · filed Apr 2017
Unity Biotechnology was a biotechnology company that is no longer operating.
BiotechBrisbane, US
Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in
Board seatRobert NelsenKristina Burow· per SEC Form D
Co-investorsage1Cycad Group LLCEcoR1 CapitalKhosla VenturesVenrock
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Board seatKristina BurowRichard Heyman· per SEC Form D
Co-investorsAvoro Capital AdvisorsCardinal PartnersNextech InvestSoftBank Vision FundVersant Ventures
Company producing world's first multi-material 3D printer capable of printing functional features with variable material properties.
Somerville, US
Jennifer A. Lewis(Executive Officer, Director)
BoardJiong Ma(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsBraemar Energy VenturesIn-Q-Tel
Subsea and terrestrial optical transport supplier whose assets, rescued by H.I.G. in 2017, are being bought by Prysmian and Fincantieri.
Allen, US
Keith Henderson(Executive Officer)inLes Barkley(Executive Officer)inPaul Colan(Executive Officer)Jon Hopper(Executive Officer, Director)inGary Otake(Executive Officer)inHerve Fevrier(Executive Officer)
Board seatClinton Bybee· per SEC Form D · $1.5M raise · filed Sep 2016
Co-investorsAristos Ventures
Accompany was a relationship intelligence and business insights platform that has been acquired by Cisco and integrated into their collaboration products suite.
Enterprise SoftwareSaaS
Ryan McDonough(Founder)in
Co-investorsCRV (Charles River Ventures)Vista Venture PartnersICONIQ CapitalIVP (Institutional Venture Partners)Venrock
Bethesda-based provider of in-home and virtual primary, behavioral and social care for low-income patients with complex needs.
HealthtechBethesda, US
Rahul Rajkumar(Executive Officer, Director)in
BoardBryan Roberts(Director)Robert Kocher(Director)Stephanie Lovell(Director)Vivian Riefberg(Director)
Co-investorsIVP (Institutional Venture Partners)VenrockVenrock Associates
Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsSR One Capital Management
Aledade is an accountable care organization (ACO) partner that works with primary care organizations to improve patient outcomes and healthcare quality.
Enterprise SoftwareHealthtechBethesda, US
Bijan Salehizadeh(Co-founder)inFarzad Mostashari(Chief Executive Officer and Co-Founder)inMat Kendall(President and Co-Founder)in
BoardRobert Kocher(Director)in
Co-investorsActivate Venture PartnersEcho Health VenturesGV (Google Ventures)Intrepid Growth PartnersIVP (Institutional Venture Partners)Lightspeed Venture Partners+12 more
BiotechCambridge, US
Tina Liu(Executive Officer, Director)David Cordo(Executive Officer)Erica Whittaker(Director)Steve Gillis(Director)
BoardBob More(Director)
Co-investorsAlta Partners
Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
BiotechDigital HealthMedical Devices
John Maraganore(Founder)inDr. Yvonne Greenstreetin
Co-investorsAtlas VentureBlackstone Life SciencesCardinal Partners
Altos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.
BiotechDeep TechLongevityBay Area, US
Richard Murray(CEO and Founder)Shinya Yamanaka(Chief Scientific Advisor and Founder)Hal Barron(Founder)inRichard Klausner(Founder)
Co-investors8VCGeneral Catalyst
Boulder-based biopharmaceutical company developing targeted small molecule cancer drugs; acquired by Pfizer in 2019.
Co-investorsBoulder Ventures
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)
BoardValentin Barsan(Director)Sean Parker(Director)
Co-investorsHitachi VenturesKleiner PerkinsOUP (Osage University Partners)SoftBank Vision FundWestlake Village BioPartners
Co-investorsAlta PartnersDC Investment PartnersLongwood FundNextech InvestPathway to CuresAtlas Venture+6 more
bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.
BiotechDeep TechHealthtechMedical Devices
Dr Mark Kotter(Founder)Przemek Obloj(CEO)Emma Pepperellin
Co-investorsForesite CapitalBlueYard CapitalDynamk CapitalGood AI CapitalHAWKTAILMetaplanet+2 more
Palo Alto biotech developing CD47/SIRPa-targeted protein immunotherapies for atherosclerosis and other cardiovascular disease.
Co-investorsGV (Google Ventures)
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)inJoanne Lager(Chief Medical Officer)inWendy DiCicco(Chief Financial Officer)inAdrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)
Co-investorsRA CapitalSanofi Ventures
Hong Kong-listed (2137.HK) biotech founded in 2018 developing infectious disease therapies, led by hepatitis B functional-cure programs.
Carrick Therapeutics is a biopharmaceutical company with a leadership team experienced in oncology drug development and commercialization.
BiotechDigital HealthHealthtechMedical Devices
Timothy Pearson(CEO)Ash Bahl(CSO)Jenny Horsfield(CBO)Stuart McIntosh(CMO)David Sutherland(VP Finance & Controller)
Co-investorsB Capital GroupB4 CapitalCambridge Innovation CapitalLightstone Ventures
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)
Co-investorsAN Venture PartnersSofinnova VenturesCasdin CapitalFidelity InvestmentsInvusRock Springs Capital
Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.
BiotechSeattle, US
Doug Williams(Executive Officer, Director)
BoardNoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)
Co-investorsEcoR1 CapitalFlagship Pioneering
Countable Labs (formerly Enumerix) develops Countable PCR, a DNA quantification technology that provides absolute target counts at single-molecule resolution as an alternative to qPCR, digital PCR, and NGS.
BiotechDeep TechHealthtechMedical Devices
Stephen Fodor(Co-Founder & Board Director)Ari Chaney(Co-Founder & Board Director)inGiovanna Prout(CEO & Board Director)in
Co-investorsF-Prime CapitalPrimer Ventures
Hong Kong-listed (HKEX: 2616) Chinese biopharmaceutical company developing oncology, immunology and inflammation therapies.
Co-investorsGIC
Curie.Bio is a biotech venture firm pairing seed capital with in-house drug discovery support for therapeutics founders.
Zach Weinberg(Founder)in
Co-investorsAlleyCorpDNA CapitalF-Prime CapitalGV (Google Ventures)Shine CapitalAlley Robotics Ventures+1 more
deCODE analyzes and interprets the human genome to identify genetic risk factors for common diseases including cardiovascular disease and cancer.
AI & Machine LearningBiotechDeep TechReykjavik, IS
Dispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.
BiotechDeep TechMedical Devices
Lex Johnson(Co-Founder and Chief Platform Officer)inRay Liu(Co-founder and Head of Synthetic Biology)Jeff Marrazzo(Founder)inSabah Oney(Chief Executive Officer)in
Encoded develops gene therapies for neurological disorders through an integrated platform approach.
Biotech
Stephanie Tagliatela(Founder)in
Co-investorsBioBritGV (Google Ventures)Illumina VenturesMenlo VenturesSoftBank Vision FundVenrock
San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.
Co-investorsDecheng CapitalAlexandriaDeerfield Management CompanyGV (Google Ventures)Nan Fung Life SciencesNorthpond Ventures
EQRx was a Cambridge, MA biopharma that aimed to sell lower-priced novel drugs; it was acquired by Revolution Medicines in 2023.
Co-investorsAndreessen HorowitzArboretum VenturesGV (Google Ventures)
Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.
BiotechDeep TechMedical Devices
Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in
Co-investorsForbionVersant VenturesAndreessen HorowitzGV (Google Ventures)
GRAIL develops a blood-based multi-cancer early detection test called Galleri that uses next-generation sequencing and machine learning to screen for multiple cancer types before symptoms appear.
BiotechDigital HealthHealthtechMedical DevicesMenlo Park, US
Co-investorsBezos Expeditions
Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.
Cambridge, US
Leslie J Williams(Executive Officer, Director)
BoardBenjamin Chen(Director)Seiji Miyahara(Director)Sacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in
Co-investors8VCTaiho Ventures, LLCTakeda Ventures
HiberCell develops therapeutic candidates targeting the Integrated Stress Response pathway to address treatment-resistant cancers, relapse, and metastasis.
BiotechMedical Devices
Julio Aguirre-Ghiso, Ph.D.(Co-Founder)
Co-investorsMagnetic VenturesRaptor Group
Homeward Health provides in-home and virtual primary care and care coordination services for Medicare Advantage patients, helping with appointment scheduling, health advocacy, insurance navigation, and access to community resources.
Digital HealthHealthtech
Co-investorsHuman Capital
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesOUP (Osage University Partners)AlexandriaDeerfield Management CompanyHBM Healthcare InvestmentsMaverick Ventures+4 more
Shanghai-based, HKEX-listed drug developer commercializing dorzagliatin, the first approved glucokinase activator for type 2 diabetes.
Co-investorsF-Prime CapitalVenrock6 Dimensions CapitalBlue Pool CapitalEight Roads VenturesPing An
A precision immunology company co-incubated with Arch Venture Partners leveraging human genetics for autoimmune disorder treatments (exited May 2024).
Co-investorsMonograph Capital Partners
Scalable, high throughput DNA sequencing platforms.
Co-investorsArtis VenturesHemisphere Ventures LLCHeran PartnersSPRINGROCK VENTURESVenrockGenesys Capital
Organ and stem cell transplant immune suppression therapies
Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.
BiotechHealthtechMedical Devices
Joseph Nolanin
Co-investorsAIFJDRF T1D FundSamsung Ventures
Seattle-based cancer immunotherapy company developing CAR-T and TCR cell therapies; acquired by Celgene, now part of Bristol-Myers Squibb.
Co-investorsBezos Expeditions
Advanced ManufacturingBiotechDeep TechMedical DevicesSeattle, US
A biopharmaceutical company developing CAR-T cell therapies for cancer treatment.
BiotechHealthtechMedical DevicesShanghai, CN
Co-investorsAcorn Pacific VenturesYuanBio Venture Capital
Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.
Co-investorsSofinnova Ventures
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)
BoardALAN L. CRANE(Director)
Co-investorsAlpha Wave GlobalFlagship PioneeringLAVLilly Asia VenturesBaillie GiffordPolaris Partners
Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.
Co-investorsAisling CapitalProspect Venture PartnersSchooner CapitalALTITUDE LIFE SCIENCE VENTURESFoley VenturesInvus
LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.
BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)
Co-investorsGV (Google Ventures)Blue Pool Capital
Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.
BiotechDeep TechHealthtech
Co-investors+ND CapitalIllumina VenturesLongwall Venture Partners LLPM VenturesOMX Ventures
Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale.
BiotechDeep TechMedical Devices
Co-investorsIllumina VenturesPerscitus LLP
Small molecule therapies to treat kidney stones
Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.
BiotechDeep TechHealthtechMedical DevicesBothell, US
Co-investorsForesite CapitalvenBio Partners8VCAxial VC
Lyell Immunopharma is a Nasdaq-listed cell therapy developer engineering T cell therapies for solid tumors and blood cancers.
Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.
Advanced ManufacturingBiotechHealthtechMedical Devices
Co-investorsCross Creek AdvisorsPfizer Venture InvestmentsSignet Healthcare PartnersSofinnova Ventures
A manufacturing company focused on domestic production of robotics, aiming to build large-scale factories and apply AI in manufacturing.
Advanced ManufacturingAI & Machine LearningRobotics
Co-investorsScribble VenturesThe Westly GroupCollaborative FundExor Ventures
Matter is a read-later app for iPhone, iPad, and web that saves articles, newsletters, threads, PDFs, and video/podcast content with parsing and search capabilities.
ConsumerMedia & EntertainmentSaaSSan Francisco, US
Ben Springwater(Founder)inRobert Mackenzie(Founder)in
Co-investorsAdapt VenturesOutliers VCY CombinatorAndreessen HorowitzCollaborative FundExor Ventures+3 more
Matter develops a consumer iOS app that helps users track positive emotions and brain activity to improve subjective well-being.
AI & Machine LearningConsumerHealthtechMental HealthWellness & Fitness
Axel Bouchon(Founder)Ben Goldhirsh(Co-founder)inChris Shiflett(Co-founder)in
Co-investorsCollaborative FundExor VenturesPolaris Partners
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)
Co-investorsJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova PartnersAlexandria+3 more
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.
AI & Machine LearningBiotechHealthtechMedical Devices
Co-investors8VCHatteras Venture PartnersNewpath Partners
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Co-investorsAtlas VentureNewpath PartnersDCVC (Data Collective)F-Prime Capital5AM VenturesDCVC Bio+1 more
San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.
Co-investorsDecheng CapitalALTITUDE LIFE SCIENCE VENTURESDomain AssociatesHillhouse CapitalNan Fung Life Sciences
Singapore A*STAR spin-off building automated nucleic acid extraction and silicon-photonics point-of-care molecular diagnostics.
ONI develops the Nanoimager, an automated super-resolution imaging system.
BiotechDeep TechHardwareMedical DevicesOxford, GB
Co-investorsArtis VenturesFuture Planet CapitalOxford Technology ManagementVertical Venture PartnersCasdin Capital
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitziGlobe PartnersAgent CapitalNewpath PartnersREDMILE
Paratus Sciences is a drug discovery company that uses AI-powered methods to identify first-in-class medicines by studying evolutionary traits, targeting serious diseases where current therapies are inadequate.
AI & Machine LearningBiotechDeep TechUnited States, US
Co-investorsClavystBioEcoR1 Capital
BiotechLos Angeles, US
William Edward Lowry(Director)Daniel Gil(Executive Officer, Director)Heather Christofk(Executive Officer)
BoardCathy Friedman(Director)
Co-investorsGV (Google Ventures)Visionary VenturesYK Bioventures
Moonwalk Biosciences is a life sciences company operating in the biotech sector.
AI & Machine LearningBiotechDeep TechHealthtechSouth San Francisco, US
Arash Jamshidi(Co-Founder, President & CTO)inAlex Aravanis(Co-Founder & CEO)in
Co-investorsAlpha Wave GlobalKhosla Ventures
Prometheus Fuels develops systems that convert intermittent renewable energy into liquid fuels for remote electrification.
Advanced ManufacturingCleantechClimate TechDeep TechEnergySanta Cruz, US
Rob McGinnis(Founder/CEO)in
Co-investorsBMW i VenturesEmles Venture PartnersExpaMaersk GrowthMetaplanetY Combinator+3 more
Protillion Biosciences develops platform technology for antibody engineering and drug discovery.
AI & Machine LearningBiotechDeep TechCarlsbad, US
Curtis Layton(CEO/Co-Founder)inDavid Walt(Co-Founder)inWill Greenleaf(Co-Founder)inRobert Hollingsworth(Chief Scientific Officer)in
BoardSean Kendall(Director)inMalek Faham(Director)in
Co-investorsIllumina Ventures
Hangzhou-based gene-editing biotech developing immune-privileged cell therapies and xenogeneic organs for transplant and cancer.
Co-investorsAlta PartnersLAVSequoia Capital
Quantum Circuits develops superconducting quantum computers using dual-rail qubits with built-in error detection, designed to accelerate the path to fault-tolerant quantum computing.
Advanced ManufacturingDeep TechHardwareQuantum ComputingMadison, US
Rob Schoelkopf(Sterling Professor, Founder)inLuigi FrunzioRay Smetsin
Co-investorsCanaan PartnersConnecticut InnovationsF-Prime CapitalFitz Gate VenturesOUP (Osage University Partners)Tribeca Venture Partners
Reactive Biosciences is a drug discovery company applying a boron-based chemistry platform to develop new medicines.
Co-investorsCanaan Partners
San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.
BiotechSan Diego, US
Marcus Boehm(Executive Officer)Robert Peach(Executive Officer)inRaymond Stevens(Director)Faheem Hasnain(Executive Officer, Director)James Schmidt(Executive Officer)Chrysa Mineo(Executive Officer)
Co-investorsOUP (Osage University Partners)Venrock
Recuro is a virtual-first digital health platform that provides primary care, behavioral health, urgent care, and supplemental benefits (pharmacy, care management, advocacy) to patients, employers, health plans, and providers.
Digital HealthHealthtechSaaSRichardson, US
Michael Brombach(Chief Executive Officer and Co-Founder)inMichael Gorton(Chief Executive Officer)inDr. Kate Sowerwine(Chief Medical Officer)John Halsey(Director)Kris Engskov(Director)William Paiva(Director)
Co-investors1843 Capital4D CapitalCortado VenturesCure VenturesGlobal Insurance Accelerator
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)Scott Biller(Director)
Co-investorsAtlas VentureForesite CapitalThe Column GroupDecheng Capital
Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.
Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US
William S. Marth(Chief Executive Officer)
BoardRobert Nelsen
Co-investors8VCCatalio Capital Management, LPGV (Google Ventures)Koch Disruptive TechnologiesLux CapitalMagnetic Ventures+4 more
Kissht is a technology-enabled digital lender in India offering personal loans up to ₹5 lakh and loans against property up to ₹30 lakh through its mobile application.
AI & Machine LearningFintechInsurTechMumbai, IN
Ranvir Singh(Chairman and Chief Executive Officer, Founder and Promoter)inKrishnan Vishwanathan(Founder and Promoter)
Co-investorsTrifecta Capital AdvisorsSnowflake VenturesFidelity InvestmentsICONIQ
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Co-investorsAndreessen HorowitzSanofi VenturesGV (Google Ventures)
BiotechMedical Devices
Co-investorsEcoR1 Capital
Scale Biosciences develops patented single-cell analysis technology that enables researchers to conduct massively parallelized sequencing at reduced cost.
AI & Machine LearningBiotechDeep Tech
Garry Nolan(Scientific Co-Founder)Frank Steemers(Scientific Co-Founder)Jay Shendure(Scientific Co-Founder)Cole Trapnell(Scientific Co-Founder)in
SciNeuro develops targeted therapeutics for neurodegenerative and age-related brain diseases by integrating patient genetics, health history, and advanced diagnostic tools.
BiotechDeep TechDigital HealthLongevityMedical DevicesRockville, US
Min Li(CEO & Director)Sam Agus(CSO/CMO)Paul Stead(CBO)
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
Co-investorsJDRF T1D FundSlater Technology FundEight Roads VenturesMPM BioImpact
Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples.
BiotechMedical DevicesCologne, DE
Co-investorsLAVLilly Asia VenturesMSA Capital
Singular Genomics develops spatial pathology technology to map molecules and cells directly in tissue for disease characterization.
BiotechDeep TechMedical Devices
John Stark(CEO)Aaron Berlin(CTO)
Co-investorsCatalio Capital Management, LPCoatue ManagementF-Prime Capital
Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases.
BiotechHealthtechLongevityWaltham, US
Dr. Xiaodong Wang(Founder)Dr. Zhiyuan Zhang(Founder)
Co-investorsF-Prime CapitalYuanBio Venture CapitalFuture Innovation
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Executive Officer, Director, Promoter)in
BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)
Co-investors8VCFrazier Life SciencesJDRF T1D FundLAVLifeforce CapitalLilly Asia Ventures+1 more
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound enhancing agents) to deliver genetic payloads to targeted sites in a redosable manner.
BiotechDeep TechDigital Health
Kenneth Greenberg(Founder)in
Co-investorsLeaps by BayerSymBiosisUCB VenturesVida VenturesVivo Capital
Biotechnology company developing blood-based diagnostic tests for neurological disorders and early-stage cancer.
Co-investorsClavystBio
Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline.
BiotechDeep TechMedical DevicesCampbell, US
Thomas James Oxley(Executive Officer, Director)Nicholas Opie(Director)inThomas Oxley(Founder)in
BoardRahul Sharma(Director)Alex Morgan(Director)inMartin Dieck(Director)
Co-investorsForepont Capital PartnersID8 InvestmentsKaleida CapitalKhosla VenturesBezos ExpeditionsIn-Q-Tel+4 more
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Co-investorsAisling CapitalQuan CapitalFlagship VenturesREDMILE
Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists.
BiotechEnterprise SoftwareHardwareHealthtechWaltham, US
Marc N. Casper(Executive Officer, Director)inAndrew J. Thomson(Executive Officer)Peter M. Wilver(Executive Officer)Seth H. Hoogasian(Executive Officer)inAlan J. Malus(Executive Officer)inEdward A. Pesicka(Executive Officer)
Co-investorsBayMed Venture PartnersCross Creek AdvisorsExcel Venture ManagementHeran PartnersOak HC/FTDomain Associates+1 more
Hong Kong-listed, Suzhou-headquartered biopharmaceutical company developing antibody therapeutics with in-house biomanufacturing.
Xueming Qian(Founder)in
Co-investorsChina Structural Reform FundFortune Venture Capital
Treeline provides IT, security, and compliance management services for fast-scaling companies, combining proprietary software automation with human expertise to build modern IT infrastructure that supports business growth.
CybersecurityDeveloper ToolsEnterprise SoftwareSaaSSan Francisco, US
Hussain Kader(Founder)in
Co-investorsAndreessen HorowitzSV AngelHAWKTAILGV (Google Ventures)OrbiMed
Treeline offers Sails, an MVC web framework for Node.js that lets developers build data-driven APIs and backends in JavaScript, using a bundled ORM (Waterline) and code-generating blueprints.
Cloud ComputingDeveloper ToolsSaaS
Co-investorsSocial StartsAndreessen HorowitzGV (Google Ventures)OrbiMed
San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.
Co-investorsLightstone VenturesMedical Excellence Capital
VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies.
BiotechHealthtechCambridge, US
Marc Kirchmeier(Vice President, Formulation Development)Egidio Nascimento(Chief Financial Officer)inDavid Anderson(Senior Vice President, Research)inJeff Baxter(President and Chief Executive Officer)inAdam T. Buckley(Vice President, Business Development)inMurray G. Smith(Executive Officer)
Co-investors5AM VenturesClarus VenturesK2 HealthVentures
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Executive Officer, Director)Andrew Bellinger(Executive Officer)
BoardJohn Evans(Director)Anthony Philippakis(Director)inKrishna Yeshwant(Director)in
Co-investorsF-Prime CapitalGV (Google Ventures)RA CapitalvenBio PartnersForesite Capital
Vesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates.
AI & Machine LearningBiotechDeep TechCambridge, US
Yasir Al-Wakeel(CEO)in
Co-investorsFlagship Pioneering
Vilya designs novel macrocycles using AI and computational biology to create medicines that don't exist in nature.
AI & Machine LearningBiotechDeep Tech
David Baker(Scientific Founder)Patrick Salveson, PhD(Co-Founder, CTO)Adam Moyer, PhD(Co-Founder, VP of Molecular Design)David Baker, PhD(Nobel laureate, Co-Founder, Director, IPD UW, Prof. Biochemistry)Gaurav Bhardwaj, PhD(Co-Founder, UW, Asst. Prof. Medicinal Chemistry)Lance Stewart, PhD, MBA(Co-Founder, CSO & COO, IPD)
Co-investorsMadrona Venture GroupMenlo VenturesNVenturesNVIDIA
Vir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities.
AI & Machine LearningBiotechDigital HealthMedical Devices
Marianne De Backer(CEO)
Co-investorsAlta PartnersSoftBank Vision Fund8VCSoftBank Group
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)Jill Goldstein(Director)
Co-investorsDroia VenturesB Capital GroupB4 CapitalVida Ventures
Walden Biosciences is a clinical-stage biotech company developing disease-modifying therapies that selectively target the kidney to treat the underlying drivers of kidney disease.
BiotechMedical Devices
Co-investorsPandect Bioventures
Xaira develops AI and machine learning tools for drug discovery and protein design, serving pharmaceutical and biotech companies.
AI & Machine LearningBiotechMedical DevicesSouth San Francisco, US
Hetu Kamisetty(Founder)Marc Tessier-Lavigne(Founder)inDr. Ci Chu(Chief Discovery Officer)Dr. Bo Wang(Chief AI Scientist)Dr. Ian McCaffery(SVP, Translational Science and Early Clinical Development)
Co-investorsBreyer CapitalF-Prime CapitalForesite CapitalLongwood FundMenlo VenturesNew Enterprise Associates (NEA)+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 30
IPOs and acquisitions across the tracked portfolioPrime MedicineNASDAQ: PRME908 DevicesNASDAQ: MASSBeam TherapeuticsNASDAQ: BEAMBoundless BioNASDAQ: BOLDEnliven TherapeuticsNASDAQ: ELVNGossamer BioNASDAQ: GOSSGRAILNASDAQ: GRALNeumora TherapeuticsNASDAQ: NMRAQuanterixNASDAQ: QTRXScholar RockNASDAQ: SRRKScholar Rock Holding Corp, Inc.NASDAQ: SRRKSeaport TherapeuticsNASDAQ: SPTXTwist BioscienceNASDAQ: TWSTVir BiotechnologyNASDAQ: VIRVoyager Therapeutics, Inc.NASDAQ: VYGRAgios PharmaceuticalsNASDAQ: AGIODenali TherapeuticsNASDAQ: DNLIErascaNASDAQ: ERASGenerate BiomedicinesNASDAQ: GENBKardiganNASDAQ: KARDKura OncologyNASDAQ: KURAMaze TherapeuticsNASDAQ: MAZEParabilis MedicinesNASDAQ: PBLSPerkinelmerNYSE: RVTYPulmatrixNASDAQ: PULMRapport TherapeuticsNASDAQ: RAPPMetseraacq. by PfizerVividion Therapeuticsacq. by BayerJUST Biotherapeuticsacq. by EvotecSagerxacq. by Supernus Pharmaceuticals
Portfolio news
latest coverage across their companiesVir Biotechnology · americanbankingnews.com · Aug 27, 2026
Enliven Therapeutics · tickerreport.com · Aug 21, 2026
Brii Biosciences · biospectrumasia.com · Aug 20, 2026
LifeMine Therapeutics · vcnewsdaily.com · Aug 19, 2026
ring · insider.fitt.co · Aug 18, 2026
Quanterix · investing.com · Aug 17, 2026
Treeline · dentistry.co.uk · Aug 14, 2026
SonoThera · fiercebiotech.com · Aug 12, 2026
Fund performance · per public LP disclosures · 6
as of Dec 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| ARCH VENTURE FUND XIII LPLPs: Texas Municipal Retirement System, Carnegie Corporation of New York, University of Texas Investment Management Company | 2023 | — | 39.8% | 1.25x | 0.00x |
| Arch IX OverageLPs: North Carolina Retirement Systems | 2016 | — | 26.0% | 2.85x | 1.89x |
| ARCH VENTURE FUND VI LPLPs: California State Teachers' Retirement System, The Regents of the University of California, Ewing Marion Kauffman Foundation +1 more | 2003 | — | 2.4% | 1.24x | 1.24x |
| ARCH VENTURE FUND IX LPLPs: North Carolina Retirement Systems, University of Texas Investment Management Company | — | — | 24.2% | 2.58x | 1.53x |
| ARCH VENTURE FUND VII LPLPs: North Carolina Retirement Systems, The Regents of the University of California, University of Texas Investment Management Company | — | — | 37.8% | 4.83x | 4.60x |
| ARCH VENTURE FUND VIII LPLPs: North Carolina Retirement Systems, University of Texas Investment Management Company | — | — | 21.6% | 3.19x | 2.44x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Public market activity · per SEC filings
what is this? ⓘ10 insider ownership filings (Forms 3/4/5)
at Kardigan, Inc. (KARD), Lyell Immunopharma, Inc. (LYEL), Metsera, Inc. (MTSR)
Files 13F institutional holdings reports · latest Aug 2026
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has ARCH Venture Partners made?
- ARCH Venture Partners has 145 tracked investments, 57 of which have exited via acquisition or IPO, including 13 dated in the last 24 months.
- What stage does ARCH Venture Partners invest at?
- ARCH Venture Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is ARCH Venture Partners's typical check size?
- ARCH Venture Partners typically writes checks of $50K – $250M.
- What sectors does ARCH Venture Partners focus on?
- ARCH Venture Partners focuses on Biotech, Deep Tech, Healthtech.
- Where is ARCH Venture Partners located?
- ARCH Venture Partners is headquartered in Chicago, US.
- Does ARCH Venture Partners lead rounds?
- ARCH Venture Partners typically participates in rounds rather than leading them.
- Who does ARCH Venture Partners co-invest with?
- ARCH Venture Partners most often shares deals with GV (Google Ventures), F-Prime Capital, Foresite Capital, among 174 tracked co-investors.
Media · Podcasts & interviews
featuring the teamSteven Gillis, PhD | Managing Director | ARCH Venture Partners
Life Science Washington · Steven Gillis
Images
Co-investors · 96
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
SoftBank Vision Fund invests globally in AI-focused companies working to transform and create industries.
Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Catalio is a New York-based investment firm focused on innovative healthcare, investing across the full lifecycle through private, public, and credit markets.
Northpond Ventures is a venture capital firm based in Bethesda, Maryland that invests in life sciences, technology, and related sectors.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
▶84 more co-investors
Nextech InvestGeneral CatalystCanaan PartnersLux CapitalAtlas VentureRA CapitalThird Rock VenturesFlagship PioneeringSofinnova VenturesNew Enterprise Associates (NEA)Domain AssociatesLeaps by Bayer+ND CapitalMenlo VenturesFoothill VenturesIn-Q-Tel6 Dimensions CapitalVida VenturesMedical Excellence CapitalLightspeed Venture PartnersArtis VenturesVersant VenturesSR One Capital ManagementForbionDeerfield Management CompanyCambridge Innovation CapitalThe Column GroupRazor's Edge VenturesM VenturesSequoia CapitalInsight PartnersCoatue ManagementInnovation EndeavorsMadrona Venture GroupS32Paladin Capital GroupAmino CapitalSofinnova PartnersMPM BioImpactFrazier Healthcare PartnersVertical Venture PartnersBain Capital Life SciencesHealthCapCure VenturesCortado VenturesCraft VenturesAlumni VenturesNotable CapitalUnknown VenturesAtomicoGreycroftSignalFireMaveronFoundryParadigmKortschak Investments L.P.Two Sigma VenturesEntrepreneur First23andMeLOI VentureBaruch Future VenturesFormation GroupIncisive VenturesStrawberry Creek VenturesEQT Life SciencesTA VenturesNeotribe VenturesIlluminate VenturesArriveJohnson & Johnson Innovation – JJDCPitbull VenturesAbingworthAt One Ventures7wire VenturesWave Digital AssetsWaverley CapitalAndera PartnersAdvent Life SciencesDFJCatalio Capital ManagementVertex Ventures HCMatrix Capital ManagementAltitude Ventures Management, LlcGENERAL INCEPTION
Firms observed investing alongside ARCH Venture Partners, from public investor directories. Shared companies are the overlap with ARCH Venture Partners's recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Founders Fund is a venture capital firm that backs technology companies building transformative products.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.